
Neuland Laboratories Limited

Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081

Fax: 040 30211602

Email: neuland@neulandlabs.com
www.neulandlabs.com

May 17, 2019

To
B S E Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB
Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47 (1) (b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Audited financial results for the year ended March 31, 2019, published in Financial Express and Andhra Prabha on May 17, 2019 for your reference.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

Encl : as above

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED	
		Quarter Ended	Year Ended	Year Ended	Year Ended	Year Ended
		31.03.2019 (Audited) (Note 2)	31.03.2018 (Audited) (Note 3)	31.03.2019 (Audited)	31.03.2018 (Audited)	31.03.2018 (Audited)
1	Revenue from operations	17,266.17	16,022.62	66,682.95	52,916.15	66,682.95
2	Net profit for the period (before tax and exceptional items)	809.05	859.19	1,983.50	1,354.03	1,393.44
3	Net profit for the period before tax	809.05	859.19	1,983.50	1,354.03	1,393.44
4	Net profit for the period after tax	672.95	805.29	1,614.34	1,180.81	1,206.29
5	Total comprehensive income for the period	618.30	841.50	1,629.33	1,200.35	1,242.60
6	"Paid-up Equity Share Capital (Face value - ₹10 each)"	1,290.05	895.49	1,290.05	895.49	895.49
7	Other equity	-	-	68,267.87	23,497.51	23,823.80
8	Equity suspense account	-	-	-	31,084.99	-
9	"Earnings Per Share (of ₹10 each) (In absolute ₹ terms)"					
	(a) Basic (Note 4)	5.25	7.22	12.83	10.59	13.06
	(b) Diluted (Note 4)	5.25	7.22	12.83	10.59	13.06

Note 1: The above is an extract of the detailed format of Audited Financial Results for the quarter and year ended March 31, 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the Stock Exchange websites and on the website of the Company i.e. www.neulandlabs.com

Note 2: The figures of the quarter ended 31 March 2019 are balancing figures between audited figure in respect of the full financial year ended 31 March 2019 and the published year to date figures upto the quarter ended 31 December 2018, which were subjected to limited review by the statutory auditors.

Note 3: Pursuant to the Scheme of Amalgamation and Arrangement ("the Scheme") duly approved by the National Company Law Tribunal, Hyderabad Bench vide their order dated 21 March 2018, Neuland Health Sciences Private Limited ("NHSPL") and Neuland Pharma Research Private Limited ("NPRPL") (together referred to as "Transferor Companies"), were merged with Neuland Laboratories Limited ("NLL"). In view of the aforesaid Scheme being effective from 1 April 2016, management has carried out necessary adjustments to all the unaudited and reviewed financial results of the Company published in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarters and year to date periods commencing from 1 April 2016 to December 2017. Adjustment to such published results have been made on the basis of separate results of the Company and the management prepared unaudited/unreviewed financial results of the erstwhile transferor companies for the relevant periods.

Accordingly, the figures for the quarter ended 31 March 2018 being the balancing figure between the audited figures in respect of the full financial year ended 31 March 2018 and the unaudited year to date figures up to the nine months ended 31 December 2017 is arrived on the basis explained above.

Note 4: The EPS for quarters has not been annualised.

By Order of the Board
For Neuland Laboratories Limited

Sd/-

Dr. D.R.Rao
Chairman & Managing Director
(DIN 00107737)

Place: Hyderabad
Date : 16 May 2019

NEULAND LABORATORIES LIMITED

(CIN : L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED	
		Quarter Ended	Year Ended	Year Ended	Year Ended	Year Ended
		31.03.2019 (Audited) (Note 2)	31.03.2018 (Audited) (Note 3)	31.03.2019 (Audited)	31.03.2018 (Audited)	31.03.2018 (Audited)
1	Revenue from operations	17,266.17	16,022.62	66,682.95	52,916.15	66,682.95
2	Net profit for the period (before tax and exceptional items)	809.05	859.19	1,983.50	1,354.03	1,393.44
3	Net profit for the period before tax	809.05	859.19	1,983.50	1,354.03	1,393.44
4	Net profit for the period after tax	672.95	805.29	1,614.34	1,180.81	1,206.29
5	Total comprehensive income for the period	618.30	841.50	1,629.33	1,200.35	1,242.60
6	"Paid-up Equity Share Capital (Face value - ₹10 each)"	1,290.05	895.49	1,290.05	895.49	895.49
7	Other equity	-	-	68,267.87	23,497.51	23,823.80
8	Equity suspense account	-	-	-	31,084.99	-
9	"Earnings Per Share (of ₹10 each) (In absolute ₹ terms)"					
	(a) Basic (Note 4)	5.25	7.22	12.83	10.59	13.06
	(b) Diluted (Note 4)	5.25	7.22	12.83	10.59	13.06

Note 1: The above is an extract of the detailed format of Audited Financial Results for the quarter and year ended March 31, 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the Stock Exchange websites and on the website of the Company i.e. www.neulandlabs.com

Note 2: The figures of the quarter ended 31 March 2019 are balancing figures between audited figure in respect of the full financial year ended 31 March 2019 and the published year to date figures upto the quarter ended 31 December 2018, which were subjected to limited review by the statutory auditors.

Note 3: Pursuant to the Scheme of Amalgamation and Arrangement ("the Scheme") duly approved by the National Company Law Tribunal, Hyderabad Bench vide their order dated 21 March 2018, Neuland Health Sciences Private Limited ("NHSPL") and Neuland Pharma Research Private Limited ("NPRPL") (together referred to as "Transferor Companies"), were merged with Neuland Laboratories Limited ("NLL"). In view of the aforesaid Scheme being effective from 1 April 2016, management has carried out necessary adjustments to all the unaudited and reviewed financial results of the Company published in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarters and year to date periods commencing from 1 April 2016 to December 2017. Adjustment to such published results have been made on the basis of separate results of the Company and the management prepared unaudited/unreviewed financial results of the erstwhile transferor companies for the relevant periods.

Accordingly, the figures for the quarter ended 31 March 2018 being the balancing figure between the audited figures in respect of the full financial year ended 31 March 2018 and the unaudited year to date figures up to the nine months ended 31 December 2017 is arrived on the basis explained above.

Note 4: The EPS for quarters has not been annualised.

By Order of the Board
For Neuland Laboratories Limited

Sd/-

Dr. D.R.Rao
Chairman & Managing Director
(DIN 00107737)

Place: Hyderabad
Date : 16 May 2019